Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.57 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7826522 | 1.00 | OTC (0.57) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL450041 | 0.95 | OTC (0.63) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL5548101 | 0.95 | OTC (0.63) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL22689763 | 0.86 | OTC (0.54) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL22689846 | 0.85 | OTC (0.53) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL6183879 | 0.84 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL14682811 | 0.84 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL18350239 | 0.84 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL6672850 | 0.84 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL5973446 | 0.84 | OTC (0.58) | OTCGSRARG2ARG1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | claimed |
| EP-4426274-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | Baxter International Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | claimed |
| US-11969522-B2 | Use of immune modulators to improve nerve regeneration | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-30 | — | — | US | claimed |
| CN-115691075-B | Early warning system based on coal mine temperature and humidity detection | 乌海市天誉煤炭有限责任公司 | 2023-08-08 | — | — | CN | claimed |
| US-11650253-B2 | State estimation method for power battery formation process based on convex space filtering | JIANGNAN UNIVERSITY (CN) | 2023-05-16 | — | — | US | claimed |
| WO-2023081681-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230140515-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. | 2023-05-04 | — | — | US | claimed |
| CN-115691075-A | Early warning system based on coal mine temperature and humidity detection | 乌海市天誉煤炭有限责任公司 | 2023-02-03 | — | — | CN | claimed |
| US-20220413052-A1 | State Estimation Method for Power Battery Formation Process Based on Convex Space Filtering | JIANGNAN UNIVERSITY (CN) | 2022-12-29 | — | — | US | claimed |
| JP-4723476-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| US-20100056480-A1 | USE OF ARGINASE INHIBITORS IN THE TREATMENT OF ASTHMA AND ALLERGIC RHINITIS | Rijks Univesiteit Groningen | 2010-03-04 | — | — | US | claimed |
| EP-2083812-A1 | USE OF ARGINASE INHIBITORS IN THE TREATMENT OF ASTHMA AND ALLERGIC RHINITIS | Rijksuniversiteit Groningen (NL) | 2009-08-05 | — | — | EP | claimed |
| WO-2008061612-A1 | USE OF ARGINASE INHIBITORS IN THE TREATMENT OF ASTHMA AND ALLERGIC RHINITIS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2008-05-29 | — | — | WO | claimed |
| EP-1596854-A4 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDRENS HOSP & RES CT OAK (US) | 2007-06-06 | — | — | EP | claimed |
| JP-2006518387-A | — | — | 2006-08-10 | — | — | JP | claimed |
| EP-1596854-A2 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | Children's Hospital & Research Center at Oakland (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050158401-A1 | Treatment and diagnosis of conditions associated with elevated arginase activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | claimed |
| WO-2004073623-A9 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDRENS HOSP & RES CT OAK (US) | 2005-01-27 | — | — | WO | claimed |
| WO-2004073623-A2 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2004-09-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | OTC 1085/4885GSR 1071/4885ARG2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.